Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 1;35(2):157-164.
doi: 10.1097/MOU.0000000000001231. Epub 2024 Oct 8.

Medical therapy for male infertility

Edoardo Pozzi  1   2 , Christian Corsini  1   2 , Andrea Salonia  1   2
Affiliations
Review

Medical therapy for male infertility

Edoardo Pozzi et al. Curr Opin Urol. .

Abstract

Purpose of review: To provide up-to-date evidence and clinical guidance on the role of medical therapy in the context of hormonal imbalances affecting human spermatogenesis.

Recent findings: Compelling evidence has accumulated over the years regarding the role of gonadotropins, selective estrogen modulators, and aromatase inhibitors to either improve or restore spermatogenesis in men with hormonal abnormalities (e.g. hypogonadotropic/hypergonadotropic hypogonadism, hyperprolactinemia) or supraphysiologic levels (e.g. exogenous testosterone/anabolic steroid use). Despite the increasing number of studies being performed, most of the available evidence relies on small nonrandomized studies, mainly in men with hypergonadotropic hypogonadism or with history of exogenous testosterone/anabolic steroid use. As such, the efficacy of medical therapy is highly variable emphasizing the necessity of randomized clinical trials and individualized approaches.

Summary: This narrative review provides clinical guidance on medical therapies for male factor infertility based on the most up-to-date evidence, focusing on treatments for hormonal abnormalities (either hypogonadotropic or hypergonadotropic hypogonadism and hyperprolactinemia) and supraphysiologic levels (and exogenous testosterone/anabolic steroid use) to improve spermatogenesis.

PubMed Disclaimer

References

    1. Rohayem J, Hauffa BP, Zacharin M, et al. Group” the “German AHHS. Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? -a multicentre prospective study of hCG/rFSH treatment outcomes during adolescence. Clin Endocrinol 2017; 86:75–87.
    1. Agarwal A, Baskaran S, Parekh N, et al. Male infertility. Lancet 2021; 397:319–333.
    1. Eisenberg ML, Esteves SC, Lamb DJ, et al. Male infertility. Nat Rev Dis Primers 2023; 9:49.
    1. Salonia A, Rastrelli G, Hackett G, et al. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers 2019; 5:38.
    1. Amory JK, Coviello AD, Page ST, et al. Serum 17-hydroxyprogesterone strongly correlates with intratesticular testosterone in gonadotropin-suppressed normal men receiving various dosages of human chorionic gonadotropin. Fertil Steril 2008; 89:380–386.

MeSH terms